

Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

September 30, 2020

Corporate Relationship Department M/s. BSE Ltd. Dalal Sreet, Fort <u>Mumbai 400 001</u> Manager – Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) <u>Mumbai 400 051</u>

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

M. Adinarayana Company Secretary & Vice President (Legal and Corp Affairs



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

PR/9/2020-2021

Press Release

Hyderabad, India, September 30th, 2020

NATCO announces launch of breast cancer medicine Lapatinib Tablets in the U.S.

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce that its marketing partner, Lupin Limited (Lupin), has launched Lapatinib Tablets, 250 mg, in the United States market after NATCO received the **final approval** for its Abbreviated New Drug Application (ANDA) from the U.S. Federal Drug Administration (USFDA). NATCO was the 1st ANDA applicant for Lapatinib Tablets, 250mg, containing a Paragraph IV certification.

Lapatinib Tablets, 250mg, is sold under Brand name TYKERB[®], of Novartis Pharmaceuticals Corporation (Novartis), which is indicated primarily for the treatment of certain types of breast cancer. For the 12 months ending June, 2020, TYKERB[®] had sales of approximately USD 61 million in the U.S. (IQVIA MAT June 2020).

Forwarded for favour of publication	
For NATCO Pharma Limited Mawe rayawers M Adinarayana Company Secretary & Vice President (Legal & Corp Affairs)	